Navigation Links
New Study Suggests Tapentadol IR for Acute Pain Is Associated With Improved Gastrointestinal Tolerability Compared to Oxycodone IR
Date:5/9/2008

tients with low back pain or pain from osteoarthritis of the knee or hip studied the tolerability of long-term exposure (90-days) to tapentadol IR. Patients were randomly assigned in a 4:1 ratio to a flexible dose of either tapentadol IR (50 or 100 mg/dose; maximum 600 mg/day) or oxycodone IR (10 or 15 mg/dose; maximum 90 mg/day) every four to six hours.

J&JPRD and Grunenthal GmbH supported this study.

J&JPRD and Ortho-McNeil-Janssen Pharmaceuticals, Inc. are wholly owned subsidiaries of Johnson & Johnson.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD) is a wholly owned subsidiary of Johnson & Johnson, the world's most broadly based producer of health care products. J&JPRD is headquartered in Raritan, N.J., and has facilities throughout Europe, the United States and Asia. J&JPRD is leveraging drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. More information can be found at http://www.jnjpharmarnd.com/.

PriCara(TM), Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.

PriCara(TM), a Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc., is a major health care company in the United States dedicated to the needs of primary care providers who serve a vital role on the frontline of medicine. For more information about the company, please visit http://www.PriCara.com.

Grunenthal

Grunenthal, a privately owned pharmaceutical company based in Aachen, Germany, discovered and started development of tapentadol. Grunenthal and J&JPRD have shared development responsibilities for tapentadol for acute and chronic pain conditions since the companies signed a licensing agreement for tapentadol in 2003.


'/>"/>

SOURCE Johnson & Johnson Pharmaceutical Research & Development,L.L.C.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
2. New Study Demonstrates ACTEMRA(R) (tocilizumab) Inhibits Progression of Joint Damage in Rheumatoid Arthritis Patients
3. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
4. Skin Flaps Deliver Cancer-fighting Therapy, ASPS Study Reveals
5. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
6. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
7. Trubion Announces Initiation of Phase 2b Study of TRU-015 for the Treatment of Rheumatoid Arthritis
8. Study Demonstrates Lexapro(R) Significantly Improves Depression Symptoms in Adolescents
9. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
10. PEAK Surgical Announces Positive Results From Preclinical Study of PEAK PlasmaBlade(TM) for Obstetric and Gynecologic Surgery
11. New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... BALTIMORE , April 20, 2015  Ameritox,s Ingenuity ... health clinicians, today presented clinical research at the National ... Orlando, Fla. , showing that nearly 25 percent ... illness (SMI) did not contain the prescribed antipsychotic medication. ... - http://photos.prnewswire.com/prnh/20150420/199663LOGO ...
(Date:4/20/2015)... , April 20, 2015  U.S. pharmacy cost increases ... to drift into the low double-digits by 2016, according to ... retirement and health solutions business of Aon plc ... changes are projected to be 9.5 percent in 2015 and ... Aon Hewitt predicts a similar rate of increase in ...
(Date:4/20/2015)... , April 20, 2015 Eli Lilly ... the investigational medicine ixekizumab was statistically superior to placebo ... (PsA), as demonstrated by the proportion of patients achieving ... assessment that represents a 20 percent reduction in disease ... of Rheumatology response criteria. During the 24-week, Phase 3 ...
Breaking Medicine Technology:Ingenuity Health Research Flags Potentially High Rate of Medication Nonadherence Among Those with Serious Mental Illness 2Ingenuity Health Research Flags Potentially High Rate of Medication Nonadherence Among Those with Serious Mental Illness 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 2Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 3Aon Analysis Shows Double-Digit Increases in U.S. Pharmacy Costs by 2016 4Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 2Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 3Lilly's Ixekizumab Met Primary Endpoint in a Phase 3 Study Investigating the Treatment of Psoriatic Arthritis 4
... Inc. (Nasdaq: STRM ) today announced financial ... ended January 31, 2011. Highlights for the ... purchase contracts for add-on licenses with existing clients totaling ... recognized during the quarter; Company completed and ...
... N.J., April 12, 2011 Novartis Pharmaceuticals Corporation ... Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) ... treatment of patients with advanced neuroendocrine tumors (NET) ... provided after presentation of data from the everolimus ...
Cached Medicine Technology:Streamline Health® Solutions Reports Q4 Results 2Streamline Health® Solutions Reports Q4 Results 3Streamline Health® Solutions Reports Q4 Results 4Streamline Health® Solutions Reports Q4 Results 5Streamline Health® Solutions Reports Q4 Results 6Streamline Health® Solutions Reports Q4 Results 7Streamline Health® Solutions Reports Q4 Results 8Streamline Health® Solutions Reports Q4 Results 9Streamline Health® Solutions Reports Q4 Results 10Streamline Health® Solutions Reports Q4 Results 11Streamline Health® Solutions Reports Q4 Results 12Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10
(Date:4/20/2015)... (PRWEB) April 20, 2015 Saint Joseph Regional ... 15 Top Health Systems by Truven Health Analytics, a leading ... quality of healthcare. SJRMC has been recognized by Truven Health ... the past four years. , According to Truven Health Analytics' ... Health Systems, in matchups with their peers, set the standard ...
(Date:4/20/2015)... A recent cross-sectional survey involving fibromyalgia patients ... 10 most beneficial therapies for fibromyalgia, no drugs were mentioned, ... only approved drugs were named. , “The biggest problem ... is only felt as long as the patient is taking ... “On the other hand, aerobic exercise and other non-drug approaches ...
(Date:4/20/2015)... 2015 Western Connecticut Health Network ... NEA-BC, FAAN who was named The Beatrice Hofstadter ... in September 2014, is transitioning from her current ... the development of Western Connecticut Health Network’s Nurse ... Donahue will be responsible for the identification and ...
(Date:4/20/2015)... 2015 Advance Home Care Supply ... that many customers would prefer not to share with others. ... a discreet delivery method allowing customers to order the products ... home without fear of a neighbor or passerby knowing what ... available now on all orders and no minimum order limit ...
(Date:4/20/2015)... Genuine fat loss results can seem virtually impossible ... the past. But what failed dieters and gym-goers don’t realize ... by adhering to five simple principles. , 1. Nutrition, No ... hours one spends working at the gym, a poor diet ... nutritional mean plan does not mean starvation, calorie counting or ...
Breaking Medicine News(10 mins):Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 2Health News:SJRMC Named a 15 Top Health System by Truven Health Analytics 3Health News:Medical Doctor in Huntsville Reveals That Aerobic Exercise Offers Best Results in Fibromyalgia Treatment 2Health News:Nursing Executive to Develop and Lead Nursing Leadership Program at Western Connecticut Health Network 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 2Health News:Advance Home Care Supply Proud to Offer Discreet Delivery For All Orders 3Health News:Guarantee Fat Loss Results With 5 Easy Tips 2Health News:Guarantee Fat Loss Results With 5 Easy Tips 3
... light to medium smokers, daily intake of non-steroidal anti-inflammatory drugs ... ,Norwegian scientists, who had conducted the studies, had said ... 65% less chance of having oral cancer than others, when ... suggested that NSAID might have anti carcinogenic effect on smokers ...
... improve the rate of recovery for the patients. Patients who had ... // having a favorable recovery than persons who have not been ... had the chance of 2.6 times more of a favorable recovery ... who had ischemic stroke to assess the usefulness of statins before ...
... a report prepared for the Health And Safety Executive, a ... of the employees,// researchers had found out that working in ... people work during nights, the levels of melatonin, or the ... with the new sleep routines. As a result, people do ...
... Technologies had developed a robotic dental drill that can make ... dental surgeon. The drill is all set to bring relief ... less painful than the common manual procedure. ,A dental ... and is generally imbedded in the gum through a long ...
... cancer is enhanced by eating processed meats, said the researchers ... Honolulu. ,Previous studies have tried to relate meat with ... have been proved to enhance carcinogenic growth in the pancreas. ... but the chemical agents that process the meat for long ...
... US department of Agriculture has recently unveiled a new guide to ... different needs. ,Based on the idea that same diet pattern ... on age, sex and the level of activity. The new plan ... gives you a diet chart once you feed in the required ...
Cached Medicine News:
... Right for the typical patient, right ... Medical ICDs, you have the ability to ... when you least expect themeven after implant. ... you need to be prepared in almost ...
... ID and Visitor Control System. A bar code-based ... compare and verify identity of those people authorized ... document interactions with all visitors and staff who ... child patient. It also helps to reduce the ...
... global companies a cost-effective and dependable ... initiatives. With die-cast metal construction, centralized ... options, and complex multi-language font support, ... Plus, the fully integrated RFID reader/encoder ...
... solid, tested XiIIIPlus platform, the R110Xifor ... of on-demand printing flexibility in tag ... such as XML for seamless integration ... inlay positioning, multiple power levels, statistics ...
Medicine Products: